Non-Liver Transplant Therapies for ATTR Amyloidosis 2022

Key Information
Source
Amyloidosis Support Groups
Year
2022
summary/abstract

Non-Liver Transplant Therapies for ATTR Amyloidosis 2022 lists different medications and therapies for treating ATTR Amyloidosis, a genetic disorder characterized by abnormal deposits of a protein called transthyretin (TTR). The table is divided into 3 categories: Tetramer Stabilizers, RNA-directed Therapies, and Gene Editing Therapies. Some of the therapies listed, such as Patisiran, Tafamidis, Inotersen, and Vutrisiran have FDA approval, while others are still in development.

Abstract Source
https://drive.google.com/file/d/1UqDGYw-xg3si8ts-m3afLFKZ0lo6DgvU/view
Authors
Jeffrey Zonder